Global Information
회사소개 | 문의 | 위시리스트

의약품 산업의 디지털 전환 : 주목 기업

Digital Transformation in the Pharmaceuticals Industry-Companies-to-Action, 2018

리서치사 Frost & Sullivan
발행일 2018년 09월 상품 코드 702308
페이지 정보 영문 66 Pages
가격
US $ 3,000 ₩ 3,612,000 Web Access (Regional License) help
리서치사의 웹사이트에 로그인할 수 있는 패스워드가 발급되며, PDF를 다운로드 받는 형태로 제공됩니다. 동일 국가 내에 있는 사업장의 모든 분들이 이용할 수 있는 라이선스이며, 이용 인원수 제한은 없습니다. 텍스트 등의 PDF 내용 편집은 불가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


의약품 산업의 디지털 전환 : 주목 기업 Digital Transformation in the Pharmaceuticals Industry-Companies-to-Action, 2018
발행일 : 2018년 09월 페이지 정보 : 영문 66 Pages

의약품 산업에 디지털 전환을 초래하는 유망 기업을 조사했으며, 산업 배경, 의약품 산업에 초래되는 가치, 혁신적 솔루션, 주요 기업 개요 등을 정리하여 전해드립니다.

제1장 개요

  • 주요 조사 결과
  • 조사 방법
  • 조사 범위·조사 세분화
  • 주요 과제
  • 디지털 전환의 주축·의약품 부문에서의 성장 기회
  • 의약품 산업의 과제 극복
  • 디지털 전환을 억제하는 주요 과제

제2장 주목 기업 : 개요

  • 주목 기업·밸류 크리에이터
  • 위협·시장 기회
  • 전략적 필수요건

제3장 시장 개요

  • 정의·솔루션 세분화
  • 주요 기업
  • 디지털 전환의 주축과 벤더 전략
  • 기업 목표와 디지털 전환 주축의 정합성

제4장 주요 기업 개요

  • 밸류체인 분석
  • 벤치마킹
  • BenevolentAI
  • Exscientia
  • Science 37
  • Transparency Life Science
  • Elemental Machines
  • iSolve
  • PillPack
  • Zephyr Health
  • Proteus Digital Health
  • uMotif

제5장 결론

  • 혁신 추구에 의한 생명과학 부문의 디지털 능력 구축
  • 결론 : 기업 분석의 요점
  • 면책사항

제6장 부록

제7장 FROST & SULLIVAN 소개

KSA 18.10.02

Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers-digitally enabled by the entry of non-traditional tech companies such as Apple, Facebook, and Google-pushing pharmaceutical companies to go beyond-the-pill. However, in the midst of this chaos, there are pioneering companies offering solutions that apply cutting-edge digital technologies such as AI, Big Data and analytics, cloud, mobile, blockchain, and Internet of Things (IoT) to build digital convergence across the pharmaceutical value chain, covering R&D, manufacturing and operations, marketing, and patient connect. This Companies to Action (C2A) analysis puts the spotlight on such game-changing, tech-enabled participants and how they are altering the status-quo by highlighting novel monetization models and strategic investment opportunities.

Research Scope:

The key objective of this study is to highlight current market dynamics, key market participants, customer segments, and evolving business opportunities. The study aims to identify pioneering companies that are capable of shaping the future through best practices implementation, visionary leadership, and innovation in business models. The company profiles offer insights around key solution offerings, target customer segments, service differentiators, and future growth strategies.

Further, the global study provides an analysis of companies segregated by market segments such as: smart R&D, flexible manufacturing, connected patients, and digital pharmacy. The analysis covers technologies such as Artificial intelligence (AI), Big Data and analytics, crowdsourcing, mobile, Industrial IoT (IIoT), IoT, cloud, blockchain, eCommerce, and so on.

The participants mentioned in the study are: iSolve, Zephyr Health, PillPack, Proteus Digital Health, BenevolentAI, Elemental Machines, Exscientia, Science 37, Transparency Life Sciences, and uMotif. It also lists the wider universe of companies that were assessed for this analysis. These companies were chosen based factors such as innovative technology development and application, hitting the right focus areas, proven success and industry recognition, and enhanced client collaborations.

Key Issues Addressed:

  • How are companies creating extraordinary value for pharmaceutical stakeholders?
  • Which are some unique companies that are introducing new and innovative solutions in the market?
  • How do these companies intend to transform the healthcare industry paradigms in the future? What is the impact of the external industry environment on this market?
  • What is their action plan and potential for growth? What are the current growth opportunities in digital transformation?
  • What are some key success factors in the pharmaceutical market?
  • Which are the companies with whom partnerships can be forged?

Table of Contents

1. EXECUTIVE SUMMARY

  • Key Findings
  • Methodology
  • Scope and Segmentation
  • Key Questions this Study will Answer
  • Pillars of Digital Transformation and Growth Opportunity in Pharmaceuticals
  • Tackling Challenges in the Pharmaceuticals Industry
  • Major Challenges Limiting Digital Transformation

2. COMPANIES-TO-ACTION OVERVIEW

  • Companies-to-Action Value Creators
  • Threats and Opportunities
  • Strategic Imperatives for Digital Transformation in Pharmaceuticals

3. MARKET OVERVIEW

  • Definition and Solution Segmentation
  • Impact of Key Market Influencers
  • Pillars of Digital Transformation and Vendor Strategies
  • C2A Targets Aligned With Pillars of Digital Transformation

4. COMPANIES-TO-ACTION PROFILES

  • Value Chain Analysis
  • Benchmarking of Top Companies-to-Action
  • BenevolentAI
  • BenevolentAI (continued)
  • Exscientia
  • Exscientia (continued)
  • Science 37
  • Science 37 (continued)
  • Transparency Life Science
  • Transparency Life Sciences (continued)
  • Elemental Machines
  • Elemental Machines (continued)
  • iSolve
  • iSolve (continued)
  • PillPack
  • PillPack (continued)
  • Zephyr Health
  • Zephyr Health (continued)
  • Proteus Digital Health
  • Proteus Digital Health (continued)
  • uMotif
  • uMotif (continued)

5. THE LAST WORD

  • Building Life Science Digital Capabilities by Innovation Tracking
  • Conclusion-Key Takeaways From the Companies-to-Action Analysis
  • Legal Disclaimer

6. APPENDIX

  • List of Vendors Assessed
  • List of Vendors Assessed (continued)
  • List of Vendors Assessed (continued)
  • List of Vendors Assessed (continued)
  • List of Vendors Assessed (continued)
  • List of Vendors Assessed (continued)
  • List of Vendors Assessed (continued)
  • List of Vendors Assessed (continued)
  • List of Exhibits

7. THE FROST & SULLIVAN STORY

  • The Frost & Sullivan Story
  • Value Proposition-Future of Your Company & Career
  • Global Perspective
  • Industry Convergence
  • 360° Research Perspective
  • Implementation Excellence
  • Our Blue Ocean Strategy
Back to Top
전화 문의
F A Q
 
BCC Research